Meeting
2014 ASCO Annual Meeting
Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Authors
Jessica C. Ley
Washington University School of Medicine in St. Louis, St. Louis, MO
Jessica C. Ley , Brian Nussenbaum , Jason Diaz , Jason Rich , Randal Paniello , Ravi Uppaluri , Wade L. Thorstad , Hiram Alberto Gay , Toni Rachocki , Jaisy Varges , Tanya Marya Wildes , Loren S. Michel , Douglas Adkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01566435 AND NCT00736944
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6013)
DOI
10.1200/jco.2014.32.15_suppl.6013
Abstract #
6013
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
The role of cetuximab in induction chemotherapy: Comparison of APF-C (nab-paclitaxel, cisplatin, 5-FU + cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
First Author: Douglas Adkins
Poster
2015 ASCO Annual Meeting
Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
First Author: Victoria Meucci Villaflor
First Author: D. Adkins
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil